DBV Technologies appoints new members of scientific advisory board
This article was originally published in Clinica
Epicutaneous diagnostics specialist DBV Technologies has appointed Gideon Lack and Philippe Eigenmann to its scientific advisory board. The new members, who are experts in paediatric food allergies, will help the company start its first US phase I trial in peanut allergy. Prof Lack is head of the children's allergy service at Guys' and St Thomas' NHS Foundation Trust, London, UK, and a professor of paediatric allergy at King's College, London, UK. Prof Eigenmann is an associate professor at the department of infants and adolescents at the H?pital Cantonal Universitaire de Genève, Switzerland.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.